Tetrandrine is a naturally occurring bisbenzylisoquinoline alkaloid isolated from the root of Stephania tetrandra S. Moore (known in Traditional Chinese Medicine as Han Fang Ji). As a leading China Tetrandrine Powder Manufacturer, TRB Bio-Tech provides high-purity pharmaceutical and nutraceutical grade Tetrandrine to support global research, clinical development, and commercial formulation.
This potent compound has garnered significant attention in modern pharmacology due to its diverse therapeutic properties. It acts as a natural calcium channel blocker, exhibiting anti-inflammatory, anti-fibrotic, and immunomodulatory effects. In recent years, global oncology and pulmonary research institutions have identified Tetrandrine as a key candidate for reversing multidrug resistance (MDR) and treating chronic inflammatory conditions such as silicosis and rheumatoid arthritis.
TRB Bio-Tech utilizes state-of-the-art extraction and purification technologies to ensure that our Tetrandrine Powder meets the most stringent international standards, offering unmatched stability, purity, and bioavailability for global buyers.
Nanjing Tong Rui Bio-Tech Co., Ltd. (TRB) is a technology-based enterprise combining research, development, production, and international sales. For over 20 years, we have remained at the forefront of the herbal extract industry, earning the prestigious 2026 Global Biotechnology and Life Sciences Award as the "Best Global Herbal Extract Provider 2026".
Our infrastructure includes three specialized manufacturing plants: a herbal extract factory, a bee product factory, and an animal extract factory. This diverse capability allows us to produce high-quality Nootropics, Brain Health Herb Extracts, Anti-Aging Herb Extracts, and Longevity Herb Extracts that receive exceptional feedback from our global clientele.
Every batch of Tetrandrine Powder is manufactured under strict GMP guidelines and is backed by a comprehensive suite of international certifications, including GMP, ISO, HACCP, ORGANIC, FDA, HALAL, and KOSHER. We ensure complete traceability, from the raw botanical sourcing of Stephania tetrandra to the final packaged API.
Clinical studies are increasingly focusing on Tetrandrine's ability to reverse Multidrug Resistance (MDR) in cancer therapies. By inhibiting P-glycoprotein (P-gp), it enhances the efficacy of standard chemotherapeutic agents, driving demand in oncology research pipelines.
With rising occupational health awareness, Tetrandrine's anti-fibrotic properties make it a critical therapeutic agent for pulmonary diseases like silicosis. Global pharmaceutical companies are actively securing long-term supply agreements for high-purity Tetrandrine.
The market is shifting toward eco-friendly extraction methods. TRB is leading this transition by implementing closed-loop solvent recovery and supercritical CO2 extraction technologies to minimize environmental impact while maximizing yield.
To ensure the highest level of safety and efficacy, TRB Bio-Tech maintains rigorous quality control protocols. Below are the standard specifications for our premium Tetrandrine Powder.
| Parameter | Specification Limit | Testing Methodology |
|---|---|---|
| Appearance | Off-white to light yellow crystalline powder | Visual Inspection |
| Assay (Purity) | ≥ 98.0% (Dry Basis) | HPLC (High-Performance Liquid Chromatography) |
| CAS Number | 518-34-3 | Reference Standard Verification |
| Loss on Drying | ≤ 1.0% | USP <731> Vacuum Oven |
| Heavy Metals | ≤ 10 ppm (Pb < 2ppm, As < 1ppm, Cd < 0.5ppm) | ICP-MS (Inductively Coupled Plasma Mass Spectrometry) |
| Residual Solvents | Meets USP <467> limits for Class 2/3 solvents | GC-MS (Gas Chromatography-Mass Spectrometry) |
| Total Plate Count | ≤ 1,000 cfu/g | Microbiological USP <61> |
| Yeast & Mold | ≤ 100 cfu/g | Microbiological USP <61> |
Sourcing raw Tetrandrine is only the first step. Global buyers often face challenges related to bioavailability, formulation compatibility, and regulatory compliance. TRB Bio-Tech provides end-to-end macro solutions to streamline your product development cycle:
By late 2026, TRB aims to transition 80% of our Tetrandrine production to supercritical CO2 extraction. This eliminates organic solvent residues entirely, providing an ultra-pure, eco-friendly product for sensitive pharmaceutical applications.
We are collaborating with leading Chinese universities to map the biosynthetic pathway of Tetrandrine. Our long-term roadmap includes using engineered yeast strains to ferment Tetrandrine, stabilizing costs and ensuring unlimited supply capacity.
TRB is developing liposomal and polymeric nanoparticle carrier systems for Tetrandrine. These advanced delivery systems will target specific tissues, reducing systemic toxicity and maximizing therapeutic indices in clinical settings.